Unit:
Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και ΈρευναLibrary of the School of Health Sciences
Supervisors info:
Κωνσταντίνος Ν. Συρίγος Καθηγητής Ιατρικής Σχολής ΕΚΠΑ
Πέτρος Μπακάκος Αναπληρωτής Καθηγητής Ιατρικής Σχολής ΕΚΠΑ
Νικολέττα Ροβίνα Επίκουρη Καθηγήτρια Ιατρικής Σχολής ΕΚΠΑ
Original Title:
Η Κλινική Σημασία της 3ης Γραμμής θεραπείας σε Αδενοκαρκίνωμα Πνεύμονα: Εμπειρία ενός κέντρου
Translated title:
The clinical impact of third-line therapy in patients with lung adenocarcinoma: A single center retrospective study
Summary:
BACKGROUND: Targeted therapies and immunotherapy, based on the proper molecular profile testing of the tumor specimens are the state- of-the-art procedure in patients with inoperable non small cell lung cancer, either non squamous (adenocarcinomas included) or squamous, leading to increase in overall survival. This fact, in addition to the relatively milder side effects of targeted therapies and immunotherapy, leads to second, third, or further line treatment schedules after disease progression.
AIM: This study tries to review retrospectively data from patients with non small cell lung cancer, particularly adenocarcinoma, who received third line treatment and to discuss possible correlations between epidemiologic, laboratory and clinical findings with survival data.
MATERIALS AND METHODS: Medical files of 728 patients with non small cell lung cancer (including adenocarcinoma) from the Oncology Unit of 3rd Dept of Medicine, Athens School of Medicine, of Sotiria General Hospital were reviewed. Among them, 111 patients that received more than two cycles of third-line treatment were selected. Almost half of them (54,1%) had a diagnosis of lung adenocarcinoma. The majority (64,9%) was stage IV at diagnosis. An extensive analysis was performed in order to determine possible correlations with survival and possible risk factors.
RESULTS: Patients that received 3rd line therapy had a progression free survival possibility of 59% at 3 months and of 20% at 6 months. Risk of disease progression was 35% lower in adenocarcinoma. Higher haematocrit levels in 3rd line therapy was correlated with decreased risk of disease progression and increased survival. Higher platelet count and white blood cell count levels in 1st and 3rd line therapy was correlated with higher risk of disease progression and decreased survival. Finally, patients with diabetes melitus tended to have a higher risk of disease progression.
CONCLUSIONS: Third-line therapy in lung adenocarcinoma is beneficent at a significant percentage of patients with a performance status 1 & 2. The lower risk of disease progression in adenocarcinoma is a possible benefit of targeted therapies, but further studies with patients with squamous carcinoma receiving immunotherapy are needed. Haematocrit, white blood cell count and platelet count seem to represent independent factors that affect survival parameters, both in 1st and 3rd line therapies.
Main subject category:
Health Sciences
Keywords:
Lung cancer, Adenocarcinoma, Chemotherapy, Third line
File:
File access is restricted only to the intranet of UoA.
Vassias Antonios MSc.pdf
2 MB
File access is restricted only to the intranet of UoA.
